RNA medicines represent a paradigm shift in treatment and prevention of critical diseases of
global significance, eg, infectious diseases. The highly successful messenger RNA (mRNA) …

Among non-viral vectors, lipid nanovectors are considered the gold standard for the delivery
of RNA therapeutics. The success of lipid nanoparticles for RNA delivery, with three products …

Ionotropic gelation is widely used to fabricate targeting nanoparticles (NPs) with
polysaccharides, leveraging their recognition by specific lectins. Despite the fabrication …

Uveitis is a sight-threatening disease that causes inflammation in the uvea; difluprednate
(DFB) is the first approved drug molecule for postoperative pain, inflammation, and …

Small interfering RNA (siRNA) molecules have limited transfection efficiency and stability,
necessitating the use of delivery systems to be effective in gene knockdown therapies. In this …

Nanomedicines based on nanoparticles rely both on the potency of the drug as well as the
efficiency of the delivery system, for which particle size plays a crucial role. For the …

Pulmonary delivery of small interfering RNA (siRNA) using nanoparticle-based delivery
systems is promising for local treatment of respiratory diseases. We designed dry powder …

The development of lipid-based mRNA delivery systems has significantly facilitated recent
advances in mRNA-based therapeutics. Liposomes, as the pioneering class of mRNA …

Lipid nanoparticles (LNPs) are the most clinically advanced RNA delivery technology, but
their efficiency is limited by low RNA release after endosome disruption. To improve RNA …

Small interfering RNA (siRNA) holds great potential to treat many difficult-to-treat diseases,
but its delivery remains the central challenge. This study aimed at investigating the suitability …